Orrick advised Twist Bioscience on its $70 million initial public offering of 5,000,000 shares of common stock. The offering priced at $14 per share and began trading on the Nasdaq Global Select Market on October 31, 2018 under the ticker symbol “TWST.” Founded in 2013, Twist manufactures synthetic genes and other DNA-based products. In addition to the offering, Twist has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the IPO price, less the underwriting discounts and commissions.
J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Allen & Company LLC and Robert W. Baird & Co. Incorporated acted as co-managers.
The Orrick team advising on the IPO was led by partners John Bautista, Pete Lamb and Christopher Austin and associates Vinella Sido, J.T. Ho and Hector Rodriguez, with additional assistance from partners Andrew Thorpe and Jason Flaherty, among others. Orrick has advised Twist since its inception.